Axsome is showcasing its latest clinical and real-world data across several CNS disorders, including major depressive disorder, Alzheimer's disease agitation, narcolepsy, and sleep apnea, at an upcoming event on September 19 and 20, 2025.

Key presentations will highlight the efficacy of Auvelity for depression, AXS-05 for Alzheimer's-related agitation, and Phase 3 results of AXS-12 for narcolepsy, emphasizing the company's focus on advancing treatments for neurological conditions.

Additional research includes analysis of residual symptoms in narcolepsy patients satisfied with treatment, led by Dr. Thorpy, and underscores the company's comprehensive approach to understanding and treating CNS disorders.

The event will feature detailed presentation information, including titles, dates, lead authors, and poster numbers, to demonstrate progress in developing innovative therapies for CNS conditions.

Axsome aims to address significant unmet needs in neurological and psychiatric health by developing differentiated treatments with novel mechanisms, targeting over 150 million affected individuals in the U.S.

The company’s presentations are designed to highlight ongoing efforts to improve patient outcomes, attract industry attention, and demonstrate its commitment to advancing neuroscience treatments.

Through these efforts, Axsome seeks to reinforce its position as a leader in developing innovative therapies for CNS disorders.

The research presented features contributions from renowned experts like Anita H. Clayton, Jeffrey Cummings, and Michael Thorpy, adding credibility and authority to the findings.

The presentations will include details on study titles, presentation schedules, lead authors, and poster numbers, emphasizing the focus on advancing CNS disorder treatments.

A poster will evaluate the safety and efficacy of AXS-05 in treating agitation in Alzheimer's patients, presented by Dr. Jeffrey Cummings, highlighting the company's focus on Alzheimer's-related symptoms.

Axsome’s portfolio includes FDA-approved treatments for major depressive disorder, narcolepsy, excessive daytime sleepiness, and migraine, with ongoing late-stage development programs for additional neurological and psychiatric conditions.

Additional data will cover AXS-12 (Sunosi) in narcolepsy, including Phase 3 topline results, subgroup analyses on residual symptoms, and the impact of solriamfetol on neuropsychological outcomes in sleep apnea patients, reflecting a comprehensive research approach.